Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Endocarditis After Transcatheter Pulmonary Valve Replacement

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Prevalence of Infective Endocarditis in Enterococcus faecalis Bacteremia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Association of Carpal Tunnel Syndrome With Amyloidosis, Heart Failure, and Adverse Cardiovascular Outcomes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Long-Term Risk of Infective Endocarditis After Transcatheter Aortic Valve Replacement

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Transcatheter Aortic Valve Replacement With a Repositionable Self-Expanding Prosthesis: The PORTICO-I Trial 1-Year Outcomes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Risk of Thromboembolism Associated With Atrial Fibrillation Following Noncardiac Surgery

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Mortality and morbidity of major congenital heart disease related to general prenatal screening for malformations

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Long-Term Risk of Infective Endocarditis After Transcatheter Aortic Valve Replacement

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Copenhagen Baby Heart Study: a population study of newborns with prenatal inclusion

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Incidence of infective endocarditis in patients considered at moderate risk

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Doff B McElhinney
  • Lars Sondergaard
  • Aimee K Armstrong
  • Lisa Bergersen
  • Robert F Padera
  • David T Balzer
  • Te-Hsin Lung
  • Felix Berger
  • Evan M Zahn
  • Robert G Gray
  • William E Hellenbrand
  • Jacqueline Kreutzer
  • Andreas Eicken
  • Thomas K Jones
  • Peter Ewert
Vis graf over relationer

BACKGROUND: Endocarditis has emerged as one of the most concerning adverse outcomes in patients with congenital anomalies involving the right ventricular outflow tract (RVOT) and prosthetic valves.

OBJECTIVES: The aim of this study was to evaluate rates and potential risk factors for endocarditis after transcatheter pulmonary valve replacement in the prospective Melody valve trials.

METHODS: All patients in whom a transcatheter pulmonary valve (TPV) was implanted in the RVOT as part of 3 prospective multicenter studies comprised the analytic cohort. The diagnosis of endocarditis and involvement of the TPV were determined by the implanting investigator.

RESULTS: A total of 309 patients underwent transcatheter pulmonary valve replacement (TPVR) and were discharged with a valve in place. The median follow-up duration was 5.1 years, and total observation until study exit was 1,660.3 patient-years. Endocarditis was diagnosed in 46 patients (median 3.1 years after TPVR), and a total of 35 patients were reported to have TPV-related endocarditis (34 at the initial diagnosis, 1 with a second episode). The annualized incidence rate of endocarditis was 3.1% per patient-year and of TPV-related endocarditis was 2.4% per patient-year. At 5 years post-TPVR, freedom from a diagnosis of endocarditis was 89% and freedom from TPV-related endocarditis was 92%. By multivariable analysis, age ≤12 years at implant (hazard ratio: 2.3; 95% confidence interval: 1.2 to 4.4; p = 0.011) and immediate post-implant peak gradient ≥15 mm Hg (2.7; 95% confidence interval: 1.4 to 4.9; p = 0.002) were associated with development of endocarditis and with development of TPV-related endocarditis (age ≤12 years: 2.8; 95% confidence interval: 1.3 to 5.7; p = 0.006; gradient ≥15 mm Hg: 2.6; 95% confidence interval: 1.3 to 5.2; p = 0.008).

CONCLUSIONS: Endocarditis is an important adverse outcome following TVPR in children and adults with post-operative congenital heart disease involving the RVOT. Ongoing efforts to understand, prevent, and optimize management of this complication are paramount in making the best use of TPV therapy. (Melody Transcatheter Pulmonary Valve [TPV] Study: Post Approval Study of the Original Investigational Device Exemption [IDE] Cohort; NCT00740870; Melody Transcatheter Pulmonary Valve Post-Approval Study; NCT01186692; and Melody Transcatheter Pulmonary Valve [TPV] Post-Market Surveillance Study; NCT00688571).

OriginalsprogEngelsk
TidsskriftJournal of the American College of Cardiology
Vol/bind72
Udgave nummer22
Sider (fra-til)2717-2728
Antal sider12
ISSN0735-1097
DOI
StatusUdgivet - 4 dec. 2018

ID: 56525245